Articles On Orthocell (ASX:OCC)

Regenerative medicine company Orthocell (ASX: OCC) has reported a record revenue of $9.19 million for the 12 months to the end of June 2025, underscoring market penetration and sales growth of its flagship nerve repair product Remplir in Au...

Highlights  Copper prices soar after tariff announcement  ASX 200 opens soft following RBA decision  Small-cap mining and tech news draws focus  The Australian share market opened softer today as investors reacted to global trade...

Orthocell is staging the US rollout of its Remplir device, including “pausing” enlisting too many distributors at once In Remplir’s first US commercial usage, an Ohioan surgeon has deployed the device successfully More than 300 investors t...

Australian companies can be the source of significant passive income if investors selectively choose the right stocks. ASX blue-chip shares can fully frank their dividends due to Australia's taxation system, resulting in larger grossed-up d...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

Highlights Lithium Universe advances with key acquisition in photovoltaic recycling technology. Surefire Resources intersects sulphides at Yidby Gold Project. St George Mining begins new geophysical work at Brazilian rare ea...

ASX-listed healthcare companies have long had an outsized impact on global markets. Think CSL Ltd (ASX: CSL), ResMed Inc (ASX: RMD), and Cochlear Ltd (ASX: COH). For shareholders who got in it early with those companies, the rewards h...

BHP Group Ltd (ASX: BHP) shares feature in countless investment portfolios and superannuation funds across the country. As a result, the performance of the mining giant's shares has a big impact on the wealth of Australians. But was this im...

WA biotech Orthocell has posted record revenue for the June quarter as sales for its nerve repair technology surge in Australia, ahead of an expected ramp up in US.

Highlights Bioxyne outpaces sector peers with performance in cannabis and health products Paradigm Biopharmaceuticals secures convertible note funding for late-stage trial Recce Pharmaceuticals and Botanix turn to debt as eq...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain. At the time of writing, the benchmark index is down 0.15% to 8,555.2 points. Four ASX shares that are rising more than most today are listed below...

Bioxyne stars with a 720% gain in the 2024-25 year Paradigm shares soar 34% after $41 million convertible note deal Biotechs turn to debt funding The ASX biotech sector’s best EOFY performer has come from left field: the local and Europ...

Orthocell Ltd (ASX: OCC) shares are starting the month on a positive note. In morning trade, the ASX All Ords stock is up 7% to $1.26. Why is this ASX All Ords stock jumping? The catalyst for today's gain has been the release of a sales upd...

Highlights  ASX 200 likely to open slightly lower despite Wall Street gains  Trade optimism lifts global equities and supports commodities  Small caps see active corporate developments and funding updates  The Australian share mar...

Tetratherix’s listed life starts on a solid note Dimerix pockets a $4.2 million milestone – with close to $1.4 billion to come Orthocell chalks up first commercial US procedure for its Remplir device Today’s ASX debut of wound management...

WA regenerative medicine firm Orthocell says it has marked another commercialisation milestone with the first successful surgical use of its nerve repair product in the US.

Good Afternoon and welcome to HotCopper Highlights for the end of Week 26, I’m Jon Davidson. In this segment, the stocks you were watching and discussing most this week, let’s get into it starting with the most viewed.  Trigg Minerals ma...

Orthocell (ASX:OCC) shares have notched upwards on Friday before lunchtime as the company announced its nerve repair product had been used successfully in a U.S.-based surgery for the first time. Listen to the HotCopper podcast for in-de...

Regenerative medicine company Orthocell (ASX: OCC) has achieved a major breakthrough in the global development of its Remplir technology with the successful completion of a first surgery in the US. Doctors at a hospital in Ohio used the com...

Highlights  ASX200 slips slightly as IT sector weighs on index  Lithium and resource stocks show upward momentum  US data fuels rate cut expectations, impacting global markets  The ASX 200 index edged lower on Thursday, closing do...

ASX falls 8.4 points, which was about 0.1% Xero sheds 4.7% on $3.9b acquisition of Melio Payments Info tech sector slumps 2%   ASX edges lower on Xero acquisition The ASX 200 has fallen 8.4 points or 0.1% in trade today, after major infor...

Botanix Pharmaceuticals (ASX:BOT) CEO Dr Howie McKibbon says investors shouldn’t rely just on management’s assertion that its anti-sweating drug Sofdra has – and we paraphrase – “the potential to be the world’s most successful dermatology d...

Orthocell says its Remplir nerve device blitzes the stitches Singular Health inks US physician network deal Clarity clearly is undervalued, say brokers   Among other auspicious events, the 19th of June marks the end of slavery in the US,...

A new study shows Orthocell’s Remplir product results in superior generation of nerve tissue and earlier return of muscle function The product allows surgeons to reduce the number of sutures required to reconnect severed nerves Existing c...

Highlights ASX 200 futures hint at a soft open amid global macro caution Fed maintains interest rates; inflation outlook revised upward Small-cap actions drive interest with regulatory approvals, trial updates The Australian share...

Medical device makers – including ASX-listed heart plays – are the likely winners from the US healthcare chaos Painchek hopes for US device approval by September Mayne Pharma flags legal action over Cosette bid but also waves an olive bra...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

Tylah Tully chats with Massachusetts General Hospital reconstructive surgeon, Harvard Professor and US Navy Captain Ian Valerio. Captain Valerio is a consultant and key opinion leader for Orthocell (ASX:OCC) and is visiting Australia to hel...

 Having produced more positive diagnostics results, Proteomics plans to launch its Promarker Endo device locally this year Immutep posts more positive trial results, this time for soft tissue sarcoma Broker values EBR Systems share price a...

Orthocell grows US distributors of its flagship nerve repair product Remplir to 12 Product granted US Food & Drug approval in April with signing of distributors ahead of schedule Remplir distributors now cover 21 US states with plans t...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Highlights  S&P/ASX200 poised to open higher following global equity rally  US-China tariff truce energizes tech, consumer, and mining sectors  Key updates from small caps including (ASX:OCC), (ASX:LVM), and (ASX:KAI)  Austral...

Orthocell receives regulatory approval to start sales of Remplir in the strategically important Hong Kong market Approval received well-ahead of initial expectations of Q4 2025 following submission in April Hong Kong approval adds to growi...

PEXA Group Ltd (ASX: PXA) shares are rising on Monday morning. At the time of writing, the property technology company's shares are up 0.5% to $11.89. What's going on with Pexa shares? Investors have been buying Pexa shares this morning aft...

Orthocell says it has moved at ‘warp speed’ to secure US distributors for its nerve repair device, marking another milestone in its commercialisation push into the world’s biggest healthcare market.

Highlights Orthocell (OCC) expands U.S. distribution network through 12 regional partners Australian Vanadium (AVL) progresses with Project Lumina's cost and design efficiency Forrestania Resources (FRS) reports drilling out...

The ASX200 has been up 0.45% at around 8,230 points. Orthocell (ASX:OCC) has been the most watched on HotCopper so far today, after appointing 12 distributors across 21 states in the U.S. The development is well ahead of expectations and...

Orthocell Ltd (ASX: OCC) shares are catching the eye again on Friday. In morning trade, the ASX All Ords stock is up 7% to $1.51. Why is this ASX All Ords stock jumping today? Investors have been buying the regenerative medicine company's s...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

The ASX energy share Woodside Energy Group Ltd (ASX: WDS) has had a rough time in the first few months of 2025. It's down close to 20% since the start of the year, as the chart below shows. Sometimes, large falls for commodity businesses ca...

Highlights: The ASX200 closed with a positive movement, reflecting growth across several sectors. The Information Technology and Real Estate sectors led the gains, while Utilities and Energy experienced declines. Companies l...

The S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain. In afternoon trade, the benchmark index is up slightly to 8,128.2 points. Four ASX shares that are rising more than most today are listed below. Here's why they are...

Are you on the lookout for ASX dividend shares to buy in May? If you are, then it could be worth checking out the two in this article that analysts are tipping as buys. Here's why they could be top buys this month: Cedar Woods Properties L...

Highlights: DY6 Metals (ASX:DY6) posted strong gallium assay results from its Malawi project, lifting its stock significantly Connected Minerals (ASX:CML) reported uranium exploration results from its Namibian prospect Intel...

You don't need thousands of dollars to be an investor — sometimes, all it takes is $500 and a plan. With markets constantly presenting new opportunities, even a small amount of capital can go a long way if you focus on quality businesses...

The S&P/ASX 200 Index (ASX: XJO) made it three for three this week on Wednesday, notching up its third positive session in a row. By the time the markets closed today, the ASX 200 had notched up a...

The ASX200 closed up 0.69% at 8,126 points. IT was the best performing sector, up 1.65%, followed by Real Estate, up 1.6%, and Discretionary and Health Care, both up 1.3%. Utilities was by far the worst performing sector, down 1.5%, f...

Tylah Tully speaks to Orthocell (ASX:OCC) chair John Van Der Wielen after the company reached another major milestone. Orthocell has now been granted access into the US$75 million Canadian market. This news comes hot on the heels of its re...

By stockpiling components, the US-focused Impedimed is taking no chances with tariffs Cashed-up Amplia forges ahead with promising pancreatic cancer trial Some biotechs are headed to the well, while others are rolling in the green stuff...

The S&P/ASX 200 Index (ASX: XJO) is fighting hard to stay in positive territory. In afternoon trade, the benchmark index is up 0.1% to 8,081.1 points. Four ASX shares that have failed to follow the market higher today are listed below...